6 To 7 Amino Acid Residues In Defined Sequence Patents (Class 530/329)
-
Patent number: 8809276Abstract: New peptides activating extracellular matrix protein synthesis in the skin, a cosmetic composition that includes such peptides as an active agent, and cosmetic care methods intended to delay or treat cutaneous signs of aging and photoaging by applying such peptides and/or cosmetic compositions are described.Type: GrantFiled: February 17, 2012Date of Patent: August 19, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8809496Abstract: It is an object of the present invention to provide a method for producing an 11-sugar sialylglycopeptide easily and with good yield and a high degree of purity on an industrial scale from defatted bird egg yolks. The present invention provides a production method of an 11-sugar sialylglycopeptide. More specifically, the present invention provides a production method of an 11-sugar sialylglycopeptide comprising: an extraction step of extracting defatted bird egg yolks with water or a salt solution to obtain a liquid extract of a glycopeptide, a precipitation step of adding the liquid extract to a water-soluble organic solvent to precipitate the glycopeptide, and a desalting step of desalting the precipitate.Type: GrantFiled: September 3, 2010Date of Patent: August 19, 2014Assignee: The Noguchi InstituteInventors: Shuichi Sugawara, Kenji Osumi
-
Patent number: 8809279Abstract: Peptide compounds of the following general formula (I): R1-(AA)n-X1-X2-X3-Lys-Lys-Gln-Lys-Trp-X4-(AA)p-R2 are disclosed herein. The peptide compounds can be used as Telomeric repeat-binding factor 2 (TRF2) protein-modulating compounds and have a preventive action on deoxyribonucleic acid (DNA) double-strand breaks. In addition, cosmetic compositions that include at least one peptide of general formula (I) in a physiologically acceptable medium are disclosed along with methods for preventing and/or treating cutaneous signs of aging and photoaging.Type: GrantFiled: April 27, 2012Date of Patent: August 19, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8809498Abstract: The invention relates to a compound having a structure according to the general formula P3-P2-P1-P1?-P2? (I), wherein residues P3, P2, P1, P1? and P2? are specifically defined and may be, e.g., certain amino acid residues. The invention further relates to the use of said compound and to a method for synthesizing a peptide.Type: GrantFiled: April 30, 2009Date of Patent: August 19, 2014Assignee: Freie Universitaet BerlinInventors: Claudia Borelli, Hans Christian Korting, Elisabeth Ruge, Hans Dieter Hoeltje, Robert Huber, Beate Koksch, Cosimo Damiano Cadicamo
-
Publication number: 20140228295Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.Type: ApplicationFiled: February 10, 2014Publication date: August 14, 2014Applicant: The Board of Trustees of The University of IllinoisInventor: Xiaoping Du
-
Publication number: 20140228541Abstract: The present application discloses compositions and methods of synthesis and use of 18F- or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may then be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the bifunctional chelating agent bound to 18F- or 19F-metal complex may be conjugated to the molecule to be labeled at a reduced temperature, e.g. room temperature.Type: ApplicationFiled: March 6, 2014Publication date: August 14, 2014Applicant: Immunomedics, Inc.Inventors: Christopher A. D'Souza, William J. McBride, David M. Goldenberg
-
Publication number: 20140228280Abstract: Disclosed is a low impurity content caspofungin pharmaceutical composition, also disclosed is a method for preparing the low impurity content caspofungin pharmaceutical composition. The caspofungin pharmaceutical composition provided in the present invention is provided with great stability.Type: ApplicationFiled: September 25, 2012Publication date: August 14, 2014Applicant: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Yunhai Hong, Ying Xue, Lixin Sha, Xiaoming Ji
-
Publication number: 20140227188Abstract: Provided herein are compositions and kits comprising a therapeutic agent linked to a cleavable substrate, wherein the cleavable substrate is capable of being cleaved by cathepsin E. Also provided are methods of treating one or more symptoms of a disease or disorder characterized by expression of cathepsin E in a subject and methods of eliminating a cancer cell characterized by expression of cathepsin E using the provided compositions and kits. Further provided herein are methods of detecting the presence of a cancer cell or detecting a cathepsin E expressing cell using a photosensitizer linked to a cleavable substrate, wherein the cleavable substrate is capable of being cleaved by cathepsin E.Type: ApplicationFiled: February 12, 2014Publication date: August 14, 2014Applicants: Board of Regents, The University of Texas System, The Methodist Hospital SystemInventors: Chin-Hsuan Tung, Wael Refat Adb-Elgaliel, Craig D. Logsdon, Zobeida Cruz-Monserrate
-
Publication number: 20140227295Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.Type: ApplicationFiled: February 11, 2014Publication date: August 14, 2014Inventors: Qiang CONG, Heng Cheng, Sanjeev Gangwar
-
Publication number: 20140227348Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.Type: ApplicationFiled: February 7, 2014Publication date: August 14, 2014Applicant: BAYLOR COLLEGE OF MEDICINEInventors: Lawrence Chan, Hideto Kojima, Tomoya Terashima
-
Patent number: 8802817Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.Type: GrantFiled: November 20, 2012Date of Patent: August 12, 2014Assignee: BMR Solutions Ltd.Inventor: Azim Turdiev
-
Patent number: 8802635Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: August 9, 2013Date of Patent: August 12, 2014Assignees: Oneday—Biotech And Pharma Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Publication number: 20140221608Abstract: An acid-cleavable peptide linker comprising aspartic acid and proline residues is disclosed. The acid-cleavable peptide linker provides an altered sensitivity to acid-hydrolytic release of peptides of interest from fusion peptides of the formula PEP1-L-PEP2. The inventive linker, L, is described in various embodiments, each of which provides substantially more rapid acid-release of peptides of interest than does a single aspartic acid-proline pair. In an additional aspect, a method of increasing the stability of an acid cleavable linkage to acid hydrolysis is also provided.Type: ApplicationFiled: April 15, 2014Publication date: August 7, 2014Applicant: E I DU PONT DE NEMOURS AND COMPANYInventors: LAURA A BEDZYK, Stephen R. Fahnestock, Tanja Maria Gruber, Daniel P. O'Keefe, Pierre E Rouviere
-
OLIGOPEPTIDE FOR TREATING LIVER FIBROSIS AND/OR TREATING HEPATITIS B AND/OR IMPROVING LIVER FUNCTION
Publication number: 20140221275Abstract: Disclosed is an oligopeptide for treating liver fibrosis and/or hepatitis B and/or improving liver function. The oligopeptide is obtained by reflux extraction via water, ethanol precipitation and isolation through a cation exchange resin column and a gelatinous resin column from a turtle shell. Pharmaceutically conventional excipients can be added to the oligopeptide prepared according to the present invention to prepare various dosage forms. The oligopeptide has good efficacy in treating liver fibrosis and improving liver function.Type: ApplicationFiled: November 1, 2011Publication date: August 7, 2014Inventor: Haimin LEI -
Publication number: 20140221274Abstract: Disclosed is a low impurity content caspofungin pharmaceutical composition, also disclosed is a method for preparing the low impurity content caspofungin pharmaceutical composition. The caspofungin pharmaceutical composition provided in the present invention is provided with great stability.Type: ApplicationFiled: September 25, 2012Publication date: August 7, 2014Inventors: Yunhai Hong, Ying Xue, Lixin Sha, Xiaoming Ji
-
Publication number: 20140221612Abstract: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimetic thereof.Type: ApplicationFiled: November 27, 2013Publication date: August 7, 2014Applicant: Sanford-Burnham Medical Research InstituteInventors: Lianglin Zhang, Jason A. Hoffman, Erkki Ruoslahti
-
Publication number: 20140221611Abstract: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.Type: ApplicationFiled: August 14, 2013Publication date: August 7, 2014Applicant: DYAX CORP.Inventors: Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James E. Booth
-
Patent number: 8796417Abstract: It is to provide an inorganic thin film of titanium dioxide or the like which is controlled at the nanoscale and a three-dimensional structure of a functional material such as semiconductor nanoparticles.Type: GrantFiled: May 24, 2006Date of Patent: August 5, 2014Assignee: Japan Science and Technology AgencyInventors: Kiyotaka Shiba, Kenichi Sano
-
Publication number: 20140212945Abstract: Disclosed are RNA targeting compounds, methods for using the subject RNA targeting compounds to treat myotonic dystrophy and other diseases are also disclosed.Type: ApplicationFiled: November 6, 2013Publication date: July 31, 2014Applicant: The Research Foundation for the State University of New YorkInventor: Matthew David Disney
-
Publication number: 20140213505Abstract: Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.Type: ApplicationFiled: March 31, 2014Publication date: July 31, 2014Inventors: Yulia A. Komarova, Uzma Saqib, Stephen M. Vogel, Asrar B. Malik
-
Publication number: 20140206839Abstract: The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.Type: ApplicationFiled: March 31, 2014Publication date: July 24, 2014Applicant: Allergan, Inc.Inventors: Gregory H. Altman, Rebecca L. Horan, Adam L. Collette, Jingsong Chen, Dennis Van Epps
-
Publication number: 20140206838Abstract: Peptide nucleic acids containing thymidine and 2-aminopyridine (M) nucleobases formed stable and sequence selective triple helices with double stranded RNA at physiologically relevant conditions. The M-modified PNA displayed unique RNA selectivity by having two orders of magnitude higher affinity for the double stranded RNAs than for the same DNA sequences. Preliminary results suggested that nucleobase-modified PNA could bind and recognize double helical precursors of microRNAs.Type: ApplicationFiled: October 29, 2013Publication date: July 24, 2014Applicant: The Research Foundation for The State University of New YorkInventors: Eriks Rozners, Thomas Zengeya
-
Patent number: 8784777Abstract: A solid phase peptide synthesis method for synthesizing a peptidyl contrast agent is disclosed. In one example, the method includes synthesizing an amino-chelator loaded resin, coupling of the amino-chelator loaded resin to the C-terminus and/or backbone of a peptide, cleaving the amino-chelator-peptide from a resin, and chelating a lanthanide metal to the amino-chelator-peptide.Type: GrantFiled: November 29, 2010Date of Patent: July 22, 2014Assignee: Case Western Reserve UniversityInventors: Mark D. Pagel, Byunghee Yoo
-
Publication number: 20140199325Abstract: The present invention provides a polypeptides capable of modulating tissue transglutarmnase-induced cell behaviour wherein the polypeptide comprises or consists of either (a) the amino acid sequence of a heparin-binding site of a tissue transglutaminase, or a functional fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof or (b) an antibody capable of binding to a heparin-binding site of a lissue transglutaminase, or an antigen-binding fragment or derivative thereof. In one embodiment, the heparin-binding site of a tissue transglutaminase comprises or consists of an amino acid sequence of SEQ ID NO: 1, The invention further provides medical uses of the polypeptides of the invention and methods of treatment using the same.Type: ApplicationFiled: April 30, 2012Publication date: July 17, 2014Applicant: AstonUniversityInventors: Russell Collighan, Martin Griffin, Kamila Pytel, Zhuo Wang
-
Patent number: 8779091Abstract: A selective targeting method is disclosed comprising contacting a library of ligands, particularly a peptide library, with an anti-target to allow the ligands to bind to the anti-target; separating the non-binding ligands from the anti-target bound ligands, contacting the non-binding anti-target ligands with a target allowing the unbound ligands to bind with the target to form a target-bound ligand complex; separating the target-bound ligand complex from ligands which do not bind to the target, and identifying the target-bound ligands on the target-bound ligand complex wherein the target-bound ligands have a KD in the range of about 10?7 to 10?10 M. Additionally claimed are the ligands identified according to the method.Type: GrantFiled: October 23, 2012Date of Patent: July 15, 2014Assignee: Danisco US Inc.Inventors: Christopher J. Murray, Pilar Tijerina, David A. Estell, Yiyou Chen
-
Patent number: 8778891Abstract: Peptides activating dermatopontin in the skin and cosmetic compositions including such peptide, in a physiologically suitable medium, are described. Methods of treating the cutaneous signs of aging and photoaging, and in particular wrinkles, sagging, and loss of volume and elasticity of the skin are also described.Type: GrantFiled: November 7, 2011Date of Patent: July 15, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8779092Abstract: The present invention concerns peptide sequences that specifically recognize cells of human hepatic metastases. The invention comprises also the use of nucleic acids coding for such peptides, as well as conjugates and formulations of such peptides for diagnostic and therapeutic purposes.Type: GrantFiled: November 30, 2007Date of Patent: July 15, 2014Assignee: Universita Degli Studi di TorinoInventors: Federico Bussolino, Serena Marchio
-
Publication number: 20140193465Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.Type: ApplicationFiled: October 10, 2013Publication date: July 10, 2014Applicant: Protagonist Therapeutics, Inc.Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
-
Publication number: 20140193844Abstract: There is described herein methods and peptides for detecting autoantibodies to NOG and/or SOST in a patient sample in order to diagnose of prognosticate Ankylosing Spondylitis in the patient.Type: ApplicationFiled: July 12, 2012Publication date: July 10, 2014Applicant: UNIVERSITY HEALTH NETWORKInventors: Florence Wing Ling Tsui, Robert Davies Inman
-
Publication number: 20140194371Abstract: A solid oxidized glutathione salt is produced by heating an oxidized glutathione at 30° C. or higher while the oxidized glutathione is brought into contact with an aqueous medium in the presence of a substance for providing a cation, to produce the salt of the oxidized glutathione and the cation as a solid, wherein the aqueous medium is composed of water and/or a water-soluble medium, and the cation is at least one selected from an ammonium cation, a calcium cation and a magnesium cation.Type: ApplicationFiled: June 28, 2012Publication date: July 10, 2014Applicant: KANEKA CORPORATIONInventors: Taku Mouri, Naoaki Taoka, Tadashi Moroshima, Koichi Kinoshita
-
Publication number: 20140186379Abstract: The present invention discloses novel macromolecule transduction domain (MTD) peptides which facilitate the traverse of a biologically active molecule across the cell membrane. Also disclosed are polynucleotides encoding the MTD peptides, methods of identifying the MTD peptides; methods of genetically engineering a biologically active molecule to have cell permeability by using the MTD peptides, methods of importing a biologically active molecule into a cell by using the MTD peptides, and uses thereof.Type: ApplicationFiled: November 27, 2013Publication date: July 3, 2014Applicant: PROCELL THERAPEUTICS INC.Inventors: Dae Woong JO, Jae Sun Ko, Jin Sook Kim, Kyung Mi Park, Jin Kyung Song, Jung Hee Lim, Thi Thuy Nga Do, Thi Lan Phuong Do, Minh Tam Duong
-
Patent number: 8765689Abstract: Peptide compounds of the general formula (I) R1-(AA)n-X1—X2-Arg-Glu-Met-Asn-Trp-X3-(AA)p-R2 modulating the survivin protein are described. Furthermore, cosmetic or pharmaceutical compositions, including at least one peptide of the general formula (I), in a physiologically acceptable medium are described. Additionally, methods for treating the cutaneous signs of ageing and photo-ageing, treating the skin against external aggressions, and limiting hair loss and/or stimulating hair growth are described.Type: GrantFiled: January 13, 2011Date of Patent: July 1, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8765681Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Type: GrantFiled: November 8, 2012Date of Patent: July 1, 2014Assignee: Pharmascience Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Publication number: 20140178381Abstract: Transport peptides, alone or attached to a cargo moiety, are capable of targeted axonal import into the spinal cord and other structures of the central nervous system. The transport peptides can be used to deliver therapeutic agents and other molecules of interest from the periphery to the central nervous system, providing a means to detect, treat or prevent neurodegenerative diseases, stroke, chronic pain and other conditions via minimally invasive techniques of administration.Type: ApplicationFiled: September 8, 2012Publication date: June 26, 2014Applicant: UNIVERSITY OF WASHINGTONInventors: Suzie H. Pun, Drew L. Sellers, Jamie M. Bergen, Philip J. Horner
-
Publication number: 20140179900Abstract: The present invention relates to the use of compounds for producing a medicament for preventing and/or treating atherosclerosis, atherosclerosis risk diseases and atherosclerosis sequelae.Type: ApplicationFiled: November 21, 2013Publication date: June 26, 2014Applicant: AFFIRIS AGInventors: Sylvia BRUNNER, Petra Luehrs, Frank Mattner, Walter Schmidt, Barbara Wittmann
-
Publication number: 20140179592Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.Type: ApplicationFiled: December 17, 2013Publication date: June 26, 2014Applicant: INCANTHERA LIMITEDInventors: Jason Gill, Paul Loadman, Rob Falconer, Lawrence Patterson, Jennifer Atkinson, Michael Bibby
-
Patent number: 8759301Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets for prostate cancer.Type: GrantFiled: February 10, 2011Date of Patent: June 24, 2014Assignee: The Regents of The University of MichiganInventors: Arul M. Chinnaiyan, Xiaoju Wang, Ram Shankar Mani
-
Publication number: 20140171377Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions, i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.Type: ApplicationFiled: September 10, 2013Publication date: June 19, 2014Applicant: Alba Therapeutics CorporationInventors: Amir Tamiz, Min Li
-
Publication number: 20140171619Abstract: A method for creating a peptide crosslinked bioactive polymeric material includes reacting a hydroxy-functionalized small molecule with a amino acid to form an amino acid functionalized monomer, reacting the amino acid functionalized monomer with a urea bond former to form a amino acid-based poly(ester urea), and reacting the amino acid-based poly(ester urea) with a peptide based crosslinker to form the peptide crosslinked bioactive polymeric material.Type: ApplicationFiled: May 25, 2012Publication date: June 19, 2014Applicant: The University of AkronInventors: Matthew Becker, Matthew Graham, Frank Harris, Fei Lin
-
Publication number: 20140170066Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.Type: ApplicationFiled: February 24, 2014Publication date: June 19, 2014Applicants: Merck & Co., Inc., Visen Medical, Inc.Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
-
Publication number: 20140161833Abstract: The invention relates to methods and compositions for preventing or treating human rhinovirus infection.Type: ApplicationFiled: February 18, 2014Publication date: June 12, 2014Applicant: Sanofi Pasteur Biologics, LLCInventors: Kirill KALNIN, Yanhua Yan, Harold Kleanthous
-
Publication number: 20140163203Abstract: The present invention provides processes for preparation of eptifibatide that involve coupling of amino acids in a (2+5), (4+3) and (3+4) sequence method. The invention further provides products produced by the described processes, novel compounds that can be used as synthetic intermediates for the preparation of eptifibatide.Type: ApplicationFiled: July 26, 2012Publication date: June 12, 2014Applicant: Laurus Labs Private LimitedInventors: Subha Nair Velayudhan, Bollu R. Babu, Venkata S. Indukuri, Seeta R. Gorantla, Venkata S. Ramakrishna, Bala M. Madivada
-
Publication number: 20140161777Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.Type: ApplicationFiled: February 13, 2014Publication date: June 12, 2014Applicant: University of Iowa Research FoundationInventors: Beverly L. Davidson, Yong Hong Chen
-
Publication number: 20140155576Abstract: The present invention provides a compound including a peptidomimetic which interacts sterically with the binding site of a F11R molecule, the peptidomimetic including a peptidomimetic having the SEQ ID NO: 4D. The present invention also provides a method for treating a disorder comprising administering peptide 4D to a mammal.Type: ApplicationFiled: October 11, 2013Publication date: June 5, 2014Inventors: Elizabeth Kornecki, Anna Babinska, Yigal H. Ehrlich
-
Publication number: 20140154192Abstract: The invention provides compounds of formula (I): (I) or salts thereof, wherein R1, R2, R3 Z, and X have any of the values defined herein, as well as compositions comprising such compounds. The compounds and compositions are useful for treating neurodegenerative disorders.Type: ApplicationFiled: July 6, 2012Publication date: June 5, 2014Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Robert Vince, Swati Sudhakar More
-
Publication number: 20140155318Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.Type: ApplicationFiled: September 3, 2013Publication date: June 5, 2014Applicant: Tel Hashomer Medical Research, Infrastructure and Services Ltd.Inventor: Amir ZLOTKIN
-
Patent number: 8741272Abstract: The invention relates to the use, as an agent for treating human perspiration, in a cosmetic composition, of amino acid derivatives of formula (I) below: The invention also relates to a cosmetic process for treating perspiration and possibly the body odour associated with human perspiration, especially underarm odour. The invention also relates to novel amino acid derivatives of formula (II) that will be defined in detail hereinbelow, and to cosmetic or dermatological compositions containing them.Type: GrantFiled: June 8, 2011Date of Patent: June 3, 2014Assignee: L'OrealInventors: Maria Dalko, Julien Hitce, Thomas Delanne
-
Publication number: 20140148378Abstract: The present invention relates to antibacterial peptides and analogs thereof, e.g., originating from, derived from, isolated and/or purified from mammalian milk, that reduce, inhibit and/or prevent the growth or proliferation of a bacterial organism.Type: ApplicationFiled: March 1, 2013Publication date: May 29, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
-
Publication number: 20140148377Abstract: Compounds are provided herein which are emetine derivatives that can be used as prodrugs which selectively undergo activation to release emetine in specific cellular conditions. In one aspect, a blocking group is incorporated onto the emetine molecule by the derivization of the N2?-position with moieties that can be selectively removed by hydrolysis in the cancer/tumor microenvironment. Such compounds are less cytotoxic than emetine and are substantially inactive in non-cancerous cells. In one aspect, the compounds described herein can be used for the treatment of metastatic and non-metastatic cancers, including, for example, breast cancer, prostate cancer, lung cancer, and leukemia.Type: ApplicationFiled: March 14, 2013Publication date: May 29, 2014Inventor: Oladapo Bakare
-
Patent number: 8735540Abstract: The present invention relates to sequentially arranged streptavidin-binding binding modules which may in particular be used as affinity tags. The affinity tags comprise at least two individual modules capable of mediating avidic binding to streptavidin.Type: GrantFiled: July 18, 2011Date of Patent: May 27, 2014Assignee: IBA GmbHInventor: Thomas Schmidt